• Partnering


IO Biotech is seeking partners to expanden and broaden the development of our pipeline.

Preferred collaborations 

  • Combinations trials with already approved products
  • Combinations trials with compounds in development
  • Research collaborations

 Our capabilities 

  • Unique and novel technology platform
    • dual-mode of action vaccines targeting immune regulating proteins
    • broad pipeline of first in class mechanism compounds
    • robust IP estate for technology platform and vaccines
  • High throughput and agile clinical development set-up
    • two completed phase I trials
    • two ongoing phase I trials
    • three planned phase I /phase II trials
  • Solid financial position funded by experienced investors
  • Experienced management team and world class scientific and clinical advisors

For more information, please contact 

Mikkel Dybkjaer

Senior Vice President, Business Development

email: This email address is being protected from spambots. You need JavaScript enabled to view it.